These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
753 related articles for article (PubMed ID: 15590953)
1. Rivastigmine for dementia associated with Parkinson's disease. Emre M; Aarsland D; Albanese A; Byrne EJ; Deuschl G; De Deyn PP; Durif F; Kulisevsky J; van Laar T; Lees A; Poewe W; Robillard A; Rosa MM; Wolters E; Quarg P; Tekin S; Lane R N Engl J Med; 2004 Dec; 351(24):2509-18. PubMed ID: 15590953 [TBL] [Abstract][Full Text] [Related]
2. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Burn D; Emre M; McKeith I; De Deyn PP; Aarsland D; Hsu C; Lane R Mov Disord; 2006 Nov; 21(11):1899-907. PubMed ID: 16960863 [TBL] [Abstract][Full Text] [Related]
3. Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Barone P; Burn DJ; van Laar T; Hsu C; Poewe W; Lane RM Mov Disord; 2008 Aug; 23(11):1532-40. PubMed ID: 18581467 [TBL] [Abstract][Full Text] [Related]
4. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy. Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922 [TBL] [Abstract][Full Text] [Related]
5. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Poewe W; Wolters E; Emre M; Onofrj M; Hsu C; Tekin S; Lane R; Mov Disord; 2006 Apr; 21(4):456-61. PubMed ID: 16229010 [TBL] [Abstract][Full Text] [Related]
7. Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Wesnes K Drugs Today (Barc); 2007 Jun; 43(6):349-59. PubMed ID: 17612707 [TBL] [Abstract][Full Text] [Related]
8. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Cummings J; Winblad B Expert Rev Neurother; 2007 Nov; 7(11):1457-63. PubMed ID: 17997695 [TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors for Parkinson's disease dementia. Maidment I; Fox C; Boustani M Cochrane Database Syst Rev; 2006 Jan; (1):CD004747. PubMed ID: 16437494 [TBL] [Abstract][Full Text] [Related]
10. Effect of rivastigmine on tremor in patients with Parkinson's disease and dementia. Gurevich TY; Shabtai H; Korczyn AD; Simon ES; Giladi N Mov Disord; 2006 Oct; 21(10):1663-6. PubMed ID: 16941467 [TBL] [Abstract][Full Text] [Related]
11. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule. Winblad B; Cummings J; Andreasen N; Grossberg G; Onofrj M; Sadowsky C; Zechner S; Nagel J; Lane R Int J Geriatr Psychiatry; 2007 May; 22(5):456-67. PubMed ID: 17380489 [TBL] [Abstract][Full Text] [Related]
12. Rivastigmine in the treatment of dementia associated with Parkinson's disease: effects on activities of daily living. Olin JT; Aarsland D; Meng X Dement Geriatr Cogn Disord; 2010; 29(6):510-5. PubMed ID: 20523050 [TBL] [Abstract][Full Text] [Related]
13. Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations. Cummings J; Emre M; Aarsland D; Tekin S; Dronamraju N; Lane R J Alzheimers Dis; 2010; 20(1):301-11. PubMed ID: 20164585 [TBL] [Abstract][Full Text] [Related]
14. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease. Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184 [TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting. Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990 [TBL] [Abstract][Full Text] [Related]
16. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Feldman HH; Ferris S; Winblad B; Sfikas N; Mancione L; He Y; Tekin S; Burns A; Cummings J; del Ser T; Inzitari D; Orgogozo JM; Sauer H; Scheltens P; Scarpini E; Herrmann N; Farlow M; Potkin S; Charles HC; Fox NC; Lane R Lancet Neurol; 2007 Jun; 6(6):501-12. PubMed ID: 17509485 [TBL] [Abstract][Full Text] [Related]
17. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease. Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease. Burns A; Spiegel R; Quarg P Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039 [TBL] [Abstract][Full Text] [Related]
19. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia. Darreh-Shori T; Jelic V Expert Opin Drug Saf; 2010 Jan; 9(1):167-76. PubMed ID: 20021294 [TBL] [Abstract][Full Text] [Related]
20. Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. Dubois B; Tolosa E; Katzenschlager R; Emre M; Lees AJ; Schumann G; Pourcher E; Gray J; Thomas G; Swartz J; Hsu T; Moline ML Mov Disord; 2012 Sep; 27(10):1230-8. PubMed ID: 22915447 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]